Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024

Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance

Budget 2025: Industry expects tax incentives and thrust on affordable healthcare

Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials

Kwality Pharmaceuticals receives SFDA GMP approval for 2 units

This certification will open new markets for the Kwality Pharma

European Commission expands Jemperli plus chemotherapy approval for endometrial cancer

Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population

Indegene wins 2025 BIG Innovation Award for Hyper-automated AI solution

Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform

Datroway approved in the US for patients with previously treated metastatic HR-positive breast cancer

Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030

Calquence combination approved in US for untreated mantle cell lymphoma

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone

AstraZeneca receives CDSCO approval to launch eculizumab in India

Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome

Dr. Kathiresan Rajasekar appointed President – International Business, Gufic Biosciences

With over 28 years of experience in the pharmaceutical industry, he is a seasoned Techno? Commercial professional and accomplished top management leader

DBT hosts webinar on Biomanufacturing for Climate Resilient Agriculture